Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Weight management is not enough for cannabinoid type 1 (CB1) receptor antagonists to become a commercial success

08 Mar 07

Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug
La Merie Business Intelligence

The new class of dipeptidyl peptidase IV (DPP-IV) inhibitors has one clear leader and many followers

01 Mar 07

Merck & Co clearly leads the field of DPP-IV inhibitors which has many followers in clinical development. The first companies already abandoned the field.
La Merie Business Intelligence

TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln

26 Feb 07

Sales of the major cancer antibodies grew by 57 % to US$ 10.6 bln in 2006. Cancer antibodies are challenging the still no. 1 selling class of erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate (6.4 %), and got ahead of TNF antibodies which posted sales of 10.3 bln (+ 25 %).
La Merie Business Intelligence

The market of recombinant coagulation factors is growing with next generation products

14 Feb 07

The growing market of recombinant coagulation factors posted 2006 sales of more than US$ 4.6 bln. The four market leaders compete with a staggered series of next generation products and face competition by new entrants into the various segments of the field
La Merie Business Intelligence

Dosing convenience is mandatory to keep pace in the pipeline race of GLP-1 analogs for type 2 diabetes

05 Feb 07

The emerging market of GLP-1 analogs with 2006 sales of US$ 430.2 mln in the first full market year of twice-daily exenatide attracts other players in the diabetes field, but urges them to top exenatide by more convenient products
La Merie Business Intelligence

Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26

02 Feb 07

A free compilation of the 2006 sales of the TOP 20 blockbuster and other major recombinant antibodies and proteins will be provided by La Merie Business Intelligence starting February 26
La Merie Business Intelligence

Global Image Re-Positioning 2007

30 Jan 07

Suddenly, there is a new global tidal wave of change all over the Asian region, the obvious signs are people on the move, new developments and properties popping up all over the region and a nouvo-consumerism is appearing at every corner, customers are buying shiny and wonderful things with beautiful packaging and companies are addressing their hunger with massive blitzes. ...
Naseem Javed

Reducing Risks of Infusion Related Reactions in Targeted Cancer Therapy

30 Jan 07

Infusion-related reactions occur with a wide variety of therapeutic agents used in the treatment of cancer but have become a particular concern of the targeted monoclonal antibody therapies. A post-hoc analysis performed on data from a recent large study suggests a way of minimising risk.
Olwen Glynn Owen

The iPhones, iPains & iProblems

16 Jan 07

The Appendage of the letter "i" to a word as an aim to create an icon is silly…
Naseem Javed

The right balance drives the field of PPAR agonist R&D

11 Jan 07

A strongly growing market of now more than US$ 6 bln in 2006 for only tow PPAR gamma agonists founds the basis for a heavily researched field of next generation mono, dual or triple PPAR agonists with fine-tuned subtype combinations
La Merie Business Intelligence

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.